Search

Your search keyword '"Béné, M.C."' showing total 116 results
Start Over Author "Béné, M.C."
116 results on '"Béné, M.C."'

2. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Author

Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., Ireland, R., Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., and Ireland, R.

Abstract

01 januari 2023, Item does not contain fulltext, This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

3. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.

Author

Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., Loosdrecht, A. van de, Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., and Loosdrecht, A. van de

Abstract

01 januari 2023, Item does not contain fulltext, BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

4. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Author

Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., Loosdrecht, A.A. van de, Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., and Loosdrecht, A.A. van de

Abstract

01 januari 2023, Item does not contain fulltext, Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34(+) CD19(-) ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

6. P56 - Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation: COMPARABLE OUTCOMES AMONG ADULT PATIENTS ALLOTRANSPLANTED FOR MYELODYSPLASTIC SYNDROME USING HAPLOIDENTICAL, MATCHED UNRELATED OR MATCHED SIBLING DONORS: A SINGLE-CENTER STUDY.

Author

Garnier, A., Jullien, M., Guillaume, T., Peterlin, P., Le Bourgeois, A., Mahe, B., Dubruille, V., Blin, N., Touzeau, C., Gastinne, T., Lok, A., Vantyghem, S., Moreau, P., Bene, M.C., Le Gouill, S., and Chevallier, P.

Published
2021
Full Text
View/download PDF

14. S874 EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA

Author

Avet-Loiseau, H., primary, Moreau, P., additional, van der Velden, V.H.J., additional, Attal, M., additional, Hulin, C., additional, Arnulf, B., additional, Corre, J., additional, Garderet, L., additional, Karlin, L., additional, Lambert, J., additional, Macro, M., additional, Perrot, A., additional, Sonneveld, P., additional, Levin, M.-D., additional, Klein, S., additional, Chiu, C., additional, Pe, L., additional, Vanquickelberghe, V., additional, de Boer, C., additional, Kampfenkel, T., additional, Vermeulen, J., additional, Wuilleme, S., additional, and Béné, M.C., additional

Published
2019
Full Text
View/download PDF

15. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Author

Schuurhuis, G.J., Heuser, M., Freeman, S., Béné, M.C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T, Hills, R.K., Hourigan, C.S., Jorgensen, J.L., Kern, W., Lacombe, F., Maurillo, L., Preudhomme, C., Reijden, B.A. van der, Thiede, C., Venditti, A., Vyas, P., Wood, B.L., Walter, R.B., Döhner, K., Roboz, G.J., Ossenkoppele, G.J., Schuurhuis, G.J., Heuser, M., Freeman, S., Béné, M.C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T, Hills, R.K., Hourigan, C.S., Jorgensen, J.L., Kern, W., Lacombe, F., Maurillo, L., Preudhomme, C., Reijden, B.A. van der, Thiede, C., Venditti, A., Vyas, P., Wood, B.L., Walter, R.B., Döhner, K., Roboz, G.J., and Ossenkoppele, G.J.

Abstract

Item does not contain fulltext

Published
2018

17. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Author

Westers, T.M. (Theresia), Cremers, E.M.P. (Eline), Oelschlaegel, U. (Uta), Johansson, U. (Ulrika), Bettelheim, P. (Peter), Matarraz, S. (S.), Orfao, A. (Alberto), Moshaver, B. (Bijan), Brodersen, L.E. (Lisa Eidenschink), Loken, M.R. (Michael), Wells, D.A. (Denise), Subirá, D. (Dolores), Cullen, C., Marvelde, J.G. (Jeroen) te, Velden, V.H.J. (Vincent) van der, Preijers, F.W.M.B. (Frank), Chu, S.-C. (Sung-Chao), Feuillard, J. (Jean), Guérin, E. (Estelle), Psarra, K. (Katherina), Porwit, A. (Anna), Saft, L. (Leonie), Ireland, R. (Robin), Milne, T. (Timothy), Béné, M.C., Witte, B.I. (Birgit), Della Porta, M.G. (Matteo), Kern, W. (Wolfgang), Loosdrecht, A.A. (Arjan) van de, Westers, T.M. (Theresia), Cremers, E.M.P. (Eline), Oelschlaegel, U. (Uta), Johansson, U. (Ulrika), Bettelheim, P. (Peter), Matarraz, S. (S.), Orfao, A. (Alberto), Moshaver, B. (Bijan), Brodersen, L.E. (Lisa Eidenschink), Loken, M.R. (Michael), Wells, D.A. (Denise), Subirá, D. (Dolores), Cullen, C., Marvelde, J.G. (Jeroen) te, Velden, V.H.J. (Vincent) van der, Preijers, F.W.M.B. (Frank), Chu, S.-C. (Sung-Chao), Feuillard, J. (Jean), Guérin, E. (Estelle), Psarra, K. (Katherina), Porwit, A. (Anna), Saft, L. (Leonie), Ireland, R. (Robin), Milne, T. (Timothy), Béné, M.C., Witte, B.I. (Birgit), Della Porta, M.G. (Matteo), Kern, W. (Wolfgang), and Loosdrecht, A.A. (Arjan) van de

Abstract

Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most flow cytometry protocols focus on the analysis of progenitor cells and the evaluation of the maturing myelomonocytic lineage. However, one of the most frequently observed features of myelodysplastic syndromes is anemia, which may be associated with dyserythropoiesis. Therefore, analysis of changes in flow cytometry features of nucleated erythroid cells may complement current flow cytometry tools. The multicenter study within the IMDSFlow Working Group, reported herein, focused on defining flow cytometry parameters that enable discrimination of dyserythropoiesis associated with myelodysplastic syndromes from non-clonal cytopenias. Data from a learning cohort were compared between myelodysplasia and controls, and results were validated in a separate cohort. The learning cohort comprised 245 myelodysplasia cases, 290 pathological, and 142 normal controls; the validation cohort comprised 129 myelodysplasia cases, 153 pathological, and 49 normal controls. Multivariate logistic regression analysis performed in the learning cohort revealed that analysis of expression of CD36 and CD71 (expressed as coefficient of variation), in combination with CD71 fluorescence intensity and the percentage of CD117+ erythroid progenitors provided the best discrimination between myelodysplastic syndromes and non-clonal cytopenias (specificity 90%; 95% confidence interval: 84–94%). The high specificity of this marker set was confirmed in the validation cohort (92%; 95% confidence interval: 86–97%). This erythroid flow cytometry marker combination may improve the evaluation of cytopenic cases with suspected myelodysplasia, particularly when combined with flow cytometry assessment of the myelomonocytic lineage.

Published
2017
Full Text
View/download PDF

19. HARMONEMIA: a universal strategy for flow cytometry immunophenotyping

Author

Lacombe, F., Bernal, E., Bloxham, D., Couzens, S., Porta, M.G. Della, Johansson, U., Kern, W., Macey, M., Matthes, T., Morilla, R., Paiva, A., Palacio, C., Preyers, F.W., Ratei, R., Siitonen, S., Allou, K., Porwit, A., and Béné, M.C.

Subjects
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Abstract

Item does not contain fulltext

Published
2016

20. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS

Author

Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., Béné, M.C., Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., and Béné, M.C.

Abstract

Item does not contain fulltext

Published
2014

21. Standardization of flow cytometry in myelodysplastic syndromes: Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Author

Loosdrecht, A.A. (Arjan) van de, Alhan, C. (Canan), Béné, M.C., Della Porta, M.G. (Matteo), Dräger, A.M. (Angelika), Feuillard, J. (Jean), Font, P. (Patricia), Germing, U. (Ulrich), Haase, D. (Detlef), Homburg, C.H. (Christa), Ireland, R. (Robin), Jansen, J.H. (Joop), Kern, W. (Wolfgang), Malcovati, L. (Luca), Marvelde, J.G. (Jeroen) te, Mufti, G.J. (Ghulam), Ogata, K. (Kiyoyuki), Orfao, A. (Alberto), Ossenkoppele, G.J. (Gert), Porwit, A. (Anna), Preijers, F.W.M.B. (Frank), Richards, S.J. (Stephen), Schuurhuis, G.J. (Gerrit Jan), Subirá, D. (Dolores), Valent, P. (Peter), Velden, V.H.J. (Vincent) van der, Vyas, P. (Paresh), Westra, A.H. (August), Witte, T. de, Wells, D.A. (Denise), Loken, M.R. (Michael), Westers, T.M. (Theresia), Loosdrecht, A.A. (Arjan) van de, Alhan, C. (Canan), Béné, M.C., Della Porta, M.G. (Matteo), Dräger, A.M. (Angelika), Feuillard, J. (Jean), Font, P. (Patricia), Germing, U. (Ulrich), Haase, D. (Detlef), Homburg, C.H. (Christa), Ireland, R. (Robin), Jansen, J.H. (Joop), Kern, W. (Wolfgang), Malcovati, L. (Luca), Marvelde, J.G. (Jeroen) te, Mufti, G.J. (Ghulam), Ogata, K. (Kiyoyuki), Orfao, A. (Alberto), Ossenkoppele, G.J. (Gert), Porwit, A. (Anna), Preijers, F.W.M.B. (Frank), Richards, S.J. (Stephen), Schuurhuis, G.J. (Gerrit Jan), Subirá, D. (Dolores), Valent, P. (Peter), Velden, V.H.J. (Vincent) van der, Vyas, P. (Paresh), Westra, A.H. (August), Witte, T. de, Wells, D.A. (Denise), Loken, M.R. (Michael), and Westers, T.M. (Theresia)

Abstract

The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter flow cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Con

Published
2009
Full Text
View/download PDF

24. Microparticle-enhanced nephelometric immunoassay of plasminogen in bovine milk

Author

Marchal, E., Haissat, S., Montagne, P., Cuilliere, M.L., Béné, M.C., Faure, G., Humbert, G., LINDEN, G., ProdInra, Migration, Laboratoire des BioSciences de l'Aliment (LBSA), and Institut National de la Recherche Agronomique (INRA)-Université Henri Poincaré - Nancy 1 (UHP)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], IMMUNOEPHELOMETRIE, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
1995

25. 137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group

Author

Westers, T.M., primary, Ireland, R., additional, Kern, W., additional, Alhan, C., additional, Balleisen, J.S., additional, Béné, M.C., additional, Bettelheim, P., additional, Burbury, K., additional, Cullen, M., additional, Cutler, J.A., additional, Porta, M.G. Della, additional, Drager, A.M., additional, Feuillard, J., additional, Font, P., additional, Germing, U., additional, Haase, D., additional, Johansson, U., additional, Kordasti, S., additional, Loken, M.R., additional, Malcovati, L., additional, te Marvelde, J.G., additional, Matarraz, S., additional, Milne, T., additional, Moshaver, B., additional, Mufti, G.J., additional, Ogata, K., additional, Orfao, A., additional, Porwit, A., additional, Psarra, K., additional, Richards, S.J., additional, Subirá, D., additional, Tindell, V., additional, Vallespi, T., additional, Valent, P., additional, van der Velden, V.H., additional, de Witte, T.M., additional, Wells, D.A., additional, Zettl, F., additional, and van de Loosdrecht, A.A., additional

Published
2011
Full Text
View/download PDF

28. Le diagnostic de tuberculose latente par le T SPOT-TB comparé à d'autres méthodes de dépistage dans le cas de patients atteints de rhumatismes inflammatoires (RI): Influence de la maladie et des traitements

Author

Dintinger, H., primary, Kennel-De-March, A., additional, Loeuille, D., additional, Costantino, F., additional, Rat, A.C., additional, Béné, M.C., additional, Pourel, J., additional, Faure, G., additional, and Valckenaere, I. Chary, additional

Published
2007
Full Text
View/download PDF

45. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.

Author

Béné, M.C., Castoldi, G., Knapp, W., Rigolin, G.M., Escribano, L., Lemez, P., Ludwig, W.-D., Matutes, E., Orfao, A., Lanza, F., and van't Veer, M.

Subjects
*PLASMINOGEN activators, *UROKINASE, *ACUTE myeloid leukemia, *GENE expression, *PLASMA cells, *MULTIPLE myeloma
Abstract

The analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma. The distribution of CD87 in acute myeloid leukemia (AML) varies according to the FAB subtype (highest expression in M5 and lowest in M0). Functionally, it is conceivable that the expression of CD87 could contribute to the invasive properties of the leukemic cells towards the skin and mucosal tissues as reflected by the clinical behavior of CD87 high cases. The lack of or weaker expression of CD87 on blast cells from ALL patients supports the concept that CD87 investigation might help in the distinction of AMLs from lymphoid malignancies. Among lymphoproliferative disorders, the expression of CD87 is exclusively found in pathological plasma cells. Since plasma cells also coexpress some adhesion molecules such as CD138 and CD56, this observation is consistent with the capacity of these cells to home in the bone compartment. High levels of soluble uPAR appear to represent an independent factor predicting worse prognosis and extramedullary involvement in multiple myeloma.Leukemia (2004) 18, 394-400. doi:10.1038/sj.leu.2403250 Published online 11 December 2003 [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

46. CSF-folate levels are decreased in late-onset AD patients.

Author

Serot, J. M., Christmann, D., Dubost, T., Béné, M.C., and Faure, G.C.

Subjects
FOLIC acid, ALZHEIMER'S disease, CEREBROSPINAL fluid, CHOROID plexus, VITAMIN B12, METHIONINE, ACETYLCHOLINE, NEURAL transmission, NEUROPHYSIOLOGY
Abstract

Summary. Folates are involved in the cerebral metabolism of cobalamine, methionine, L-tyrosine and acetylcholine. Remarkably CSF-folate levels are 3 to 4 times higher than blood-folate levels. To reach the brain, folates are actively transported by choroid plexus (CP) as well as vitamins B6, B12, C and E. Epithelial atrophy having been reported in aging and in Alzheimer's disease (AD), we measured the CSF folate-levels of 126 patients, including 30 AD consecutive patients to evaluate whether CP functions of folate-transport were impaired. CSF-folate concentrations did not vary with age (10.47 ± 1.93 ng/ml between 20 and 60 years; 9.96 ± 2.01 ng/ml in elderly control patients older than 60 years of age, p > 0.05) while late-onset AD patients had significantly lower CSF-folate levels (8.26 ± 1.82 ng/ml, p < 0.001). These data support a specific alteration of CP transport function in AD patients. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

48. Recurrent mutation in the PIEZO1 gene in two families of hereditary xerocytosis with fetal hydrops.

Author

Beneteau, C., Thierry, G., Blesson, S., Le Vaillant, C., Picard, V., Béné, M.C., Eveillard, M., and Le Caignec, C.

Subjects
GENETIC mutation, PROTEIN genetics, EDEMA
Abstract

A letter to the editor is presented which discusses the repeated mutation in the mechanotransduction protein PIEZO1 gene in two families of hereditary xerocytosis (HX) with fetal hydrops.

Published
2014
Full Text
View/download PDF

49. Recurrent pregnancy loss: which immunological laboratory tests?

Author

Faure, G.C., Béné, M.C., and Barbarino-Monnier, P.

Subjects
*PREGNANCY, *ABORTION, *AUTOIMMUNITY, *LUPUS erythematosus, *IMMUNOGLOBULINS
Abstract

Recurrent unexplained abortions are defined as at least two successive abortions during the first trimester of pregnancy. Implication of autoimmunity processes is now widely recognized. The list of biological assays proposed in recurrent abortions is inspired from immunological exploration of systemic lupus erythematosus in which pregnancy usually induces high risk for the conception product. Other assays derive from immunological hypotheses explaining the tolerance paradox of pregnancy, but many have not yet been established and will still require clinical research protocols. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results